Clinical Trial Update: GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

The GEMHDM2014 trial evaluating Gem-HDM HDT and autologous stem cell transplant for relapsed/refractory lymphoma has been terminated after Phase 1/Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Gem-HDM HDT plus Autologous Stem Cell Transplant

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Hodgkin's Lymphoma - Relapsed/Refractory, Non-Hodgkin's Lymphoma - Aggressive | Phase 1, Phase 2 | Status: TERMINATED